These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3124452)

  • 1. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
    Di Raimondo F; LaPushin R; Hersh EM
    Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
    Griffiths SD; Cawley JC
    Leukemia; 1988 Jun; 2(6):377-81. PubMed ID: 3374170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
    Sone S; Utsugi T; Nii A; Ogura T
    J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
    Grönberg A; Ferm M; Tsai L; Kiessling R
    Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
    Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
    Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
    Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
    Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
    Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B; Rees RC
    Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
    Djeu JY; Blanchard DK
    Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
    Reiter Z; Tomson S; Ozes ON; Taylor MW
    Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
    Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
    Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
    Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
    Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.